Advertisement

Topics

First long─term efficacy analysis on effect of GSK's Benlysta on rate of organ damage progression in SLE versus standard therapy alone

08:25 EST 10 Nov 2017 | PharmaBiz

GSK has announced results of the first study assessing levels of organ damage in patients with active systemic lupus erythematosus (SLE) treated with Benlysta (belimumab) plus standard of care (SoC) versus

Original Article: First long─term efficacy analysis on effect of GSK's Benlysta on rate of organ damage progression in SLE versus standard therapy alone

NEXT ARTICLE

More From BioPortfolio on "First long─term efficacy analysis on effect of GSK's Benlysta on rate of organ damage progression in SLE versus standard therapy alone"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...